Business
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devicesAll-stock licensing structure aligns the
About this update from Ainos, Inc.
[{"type":"text","content":"Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devicesAll-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders' SAN DIEGO, CA / ACCESSWIRE / August 9, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on novel AI-powered point-of-care testing (\"POCT\") and VELDONA low-dose interferon therapeutics, today announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology (\"TCNT\"), the Company's affiliate and product co-developer.TCNT agreed to assign and grant exclusive, irrevocable, and perpetual licenses of 10 invention patents and patent applications related to gas sensors and medical devices in exchange for the Company's shares of common stock with a total value of approximately US$5.4 million. The licensed patents cover multiple regions, including the U.S., Germany, China, Japan and Taiwan.\"I believe this licensing will bolster our AI Nose and POCT technologies as we advance our AI Nose and POCT pipeline, including progressing our leading volatile organic compounds (\"VOC\") POCT candidate, Ainos Flora, and jointly developing a VOC sensing platform with our Japanese partners. We are also moving forward with the Next-Gen Ainos Flora with an implementation of NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff. This all-stock licensing structure aligns TCNT's interest with Ainos shareholders' while preserving cash for our growth,\" Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented.About Ainos, Inc.Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.The name \"Ainos\" is a combination of \"AI\" and \"Nose\" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https...